Advancing Engineered Living Therapeutics (2020–2026): Clinical Progress, Translational Challenges, and Next-Generation Optimization Strategies
Engineered Living Therapeutics (ELTs)—or engineered live biotherapeutic products (eLBPs)—represent a transformative class of living medicines in which probiotic microbes are programmed with synthetic genetic circuits to sense disease biomarkers and deliver targeted therapeutic payloads in situ. Between 2020 and 2026, landmark preclinical and early-stage clinical studies (including SYNB1934, NOV-001, SYNB1891, and AG019) successfully demonstrated human biosafety and biological activity across metabolic disorders, solid tumors, and autoimmune diseases. However, translating these early milestones into approved Phase 3 medicines requires overcoming key biological and engineering hurdles, including gastric acid loss, transient gut residence, plasmid instability, basal promoter leakage, and horizontal gene transfer (HGT). Building upon these foundational achievements, this mini-review synthesizes representative clinical platforms from 2020 to 2026 and outlines four constructive optimization pillars: protective hydrogel encapsulation with mucosal adhesion, chromosomal circuit integration, dual-input AND-gate sensing, and multi-layered CRISPR/split-gene biocontainment. Together, these strategies provide a practical roadmap for advancing safe, durable, and clinically effective living therapeutics.
Authors
- Avinash kumar Verma (ORCID: https://orcid.org/0009-0003-1522-5931)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-19
- DOI
- https://doi.org/10.5281/zenodo.24377349
- Primary Topic
- Bacterial Cancer Therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00